MedTrace Logo

Alefacept Mechanism of Action in Psoriasis

NCT00150982 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2008-08-07

No results posted yet for this study

Summary

To determine the mechanism of action of alefacept in patients with psoriasis.

Conditions

Interventions

DRUG

Mechanism of action of alefacept

Sponsors & Collaborators

  • Biogen

    collaborator INDUSTRY

  • University of Medicine and Dentistry of New Jersey

    lead OTHER

Principal Investigators

  • Alice Gottlieb, MD, PhD · Rutgers, The State University of New Jersey

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-09-30
Completion
2005-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00150982 on ClinicalTrials.gov